INTERACTION OF INTRAVENOUS DILTIAZEM WITH LOVASTATIN

静脉注射地尔硫卓与洛伐他汀的相互作用

• 批准号: 6117842
• 负责人: D CRAIG BRATER
• 金额: $ 1.7万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6117842
• 关键词: clinical research; clinical trials; cytochrome P450; diltiazem; drug interactions; gastrointestinal system; human subject; intravenous administration; liver; lovastatin; oral administration; pharmacokinetics

This study will assess whether or not a commonly used calcium antagonist, namely diltiazem, that is known to have the capacity to block cytochrome P450 3A4, and which has been shown in out previous study to result in a drug interaction with lovastatin when given orally will produce the same interaction when given by the parenteral route. The protocol will evaluate whether lovastatin is susceptible to pharmacokinetic interactions that effect the formation of active moieties when diltiazem is given intravenously. The specific aims of the study are to determine whether the observed interaction of diltiazem with lovastatin, occurs at the interstinal level or in the liver. Intravenous therapy with diltiazem will help answer this question by bypassing the intestinal cytochrome P450 3A4.

这项研究将评估是否常用的钙拮抗剂， 即Diltiazem，已知具有阻断细胞色素的能力 P450 3A4，并且在先前的研究中已显示出来，导致了 口服时，药物与lovastatin相互作用会产生相同的药物 由肠胃外路线给出时相互作用。该协议将评估 lovastatin是否容易受到药代动力学相互作用的影响 在给出diltiazem时影响主动部分的形成 静脉注射。 研究的具体目的是确定是否观察到 diltiazem与lovastatin的相互作用发生在肠间层 或在肝脏中。 Diltiazem的静脉治疗将有助于回答这一点 通过绕过肠细胞色素P450 3A4的问题。